Satoshi Igawa

1.7k total citations
100 papers, 1.2k citations indexed

About

Satoshi Igawa is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Satoshi Igawa has authored 100 papers receiving a total of 1.2k indexed citations (citations by other indexed papers that have themselves been cited), including 80 papers in Oncology, 63 papers in Pulmonary and Respiratory Medicine and 25 papers in Molecular Biology. Recurrent topics in Satoshi Igawa's work include Lung Cancer Treatments and Mutations (59 papers), Lung Cancer Research Studies (50 papers) and Neuroendocrine Tumor Research Advances (21 papers). Satoshi Igawa is often cited by papers focused on Lung Cancer Treatments and Mutations (59 papers), Lung Cancer Research Studies (50 papers) and Neuroendocrine Tumor Research Advances (21 papers). Satoshi Igawa collaborates with scholars based in Japan, United States and Australia. Satoshi Igawa's co-authors include Jiichiro Sasaki, Noriyuki Masuda, Sakiko Otani, Tomoya Fukui, Masato Katagiri, Asuka Tsuya, Nobuyuki Yamamoto, Katsuhiko Naoki, Yukiko Nakamura and Masaru Kubota and has published in prestigious journals such as Journal of Clinical Oncology, PLoS ONE and Cancer.

In The Last Decade

Satoshi Igawa

95 papers receiving 1.2k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Satoshi Igawa Japan 18 755 597 299 281 164 100 1.2k
Shigeki Umemura Japan 24 1.2k 1.5× 841 1.4× 633 2.1× 334 1.2× 217 1.3× 112 2.0k
Yuki Matsumura Japan 18 487 0.6× 465 0.8× 188 0.6× 186 0.7× 80 0.5× 69 986
Adrian Langleben Canada 17 725 1.0× 416 0.7× 316 1.1× 167 0.6× 40 0.2× 55 1.1k
Yuichi Sakamori Japan 19 1.0k 1.3× 932 1.6× 330 1.1× 127 0.5× 47 0.3× 81 1.5k
Y. Ichinose Japan 20 721 1.0× 922 1.5× 211 0.7× 94 0.3× 104 0.6× 78 1.3k
C. A. Angeletti Italy 16 419 0.6× 383 0.6× 384 1.3× 140 0.5× 166 1.0× 34 990
Wieneke A. Buikhuisen Netherlands 16 422 0.6× 623 1.0× 189 0.6× 255 0.9× 109 0.7× 35 1.1k
Kaname Nosaki Japan 19 976 1.3× 913 1.5× 366 1.2× 149 0.5× 51 0.3× 91 1.4k
Eileen Regan United States 16 620 0.8× 238 0.4× 200 0.7× 361 1.3× 255 1.6× 34 907

Countries citing papers authored by Satoshi Igawa

Since Specialization
Citations

This map shows the geographic impact of Satoshi Igawa's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Satoshi Igawa with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Satoshi Igawa more than expected).

Fields of papers citing papers by Satoshi Igawa

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Satoshi Igawa. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Satoshi Igawa. The network helps show where Satoshi Igawa may publish in the future.

Co-authorship network of co-authors of Satoshi Igawa

This figure shows the co-authorship network connecting the top 25 collaborators of Satoshi Igawa. A scholar is included among the top collaborators of Satoshi Igawa based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Satoshi Igawa. Satoshi Igawa is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Horinouchi, Hidehito, Shogo Nomura, Satoshi Igawa, et al.. (2023). Reconsidering the Cutoff Value for Sensitive and Refractory Relapses in Extensive-Stage SCLC in the Era of Immunotherapy. Journal of Thoracic Oncology. 19(2). 325–336. 9 indexed citations
2.
Igawa, Satoshi, Hiroki Yamamoto, Yuki Akazawa, et al.. (2023). The Glasgow Prognostic Score Predicts Survival Outcomes in Patients with Extensive-Stage Small Cell Lung Cancer. Oncology. 101(11). 695–704. 3 indexed citations
3.
Nakahara, Yoshiro, Hideaki Manabe, Sakiko Otani, et al.. (2022). Promising Response to Dabrafenib Plus Trametinib in a Patient with Peritoneal Carcinomatosis from Non Small Lung Cancer Harboring BRAF V600E Mutation. OncoTargets and Therapy. Volume 15. 1369–1374. 4 indexed citations
4.
Igawa, Satoshi, Masanori Yokoba, Akira Takakura, et al.. (2021). Real-world evaluation of second line chemotherapy for patients with advanced non-small cell lung cancer harboring preexisting interstitial lung disease. Investigational New Drugs. 40(1). 182–189. 2 indexed citations
5.
Igawa, Satoshi, Masashi Kasajima, Hideaki Manabe, et al.. (2020). <p>Impact of Amrubicin Monotherapy as Second-Line Chemotherapy on Outcomes in Elderly Patients with Relapsed Extensive-Disease Small-Cell Lung Cancer</p>. Cancer Management and Research. Volume 12. 4911–4921. 2 indexed citations
6.
Igawa, Satoshi, Tomoya Fukui, Jiichiro Sasaki, et al.. (2020). Impact of neutrophil-to-lymphocyte ratio in patients with EGFR-mutant NSCLC treated with tyrosine kinase inhibitors. Investigational New Drugs. 38(3). 885–893. 14 indexed citations
7.
Igawa, Satoshi, Takaaki Ono, Tetsuya Ozawa, et al.. (2019). EP1.01-68 Impact of EGFR Genotype on the Efficacy of Osimertinib in Patients with Non-Small Cell Lung Cancer: A Prospective Observational Study. Journal of Thoracic Oncology. 14(10). S938–S938. 1 indexed citations
8.
9.
Nagashio, Ryo, Shi‐Xu Jiang, Masaaki Ichinoe, et al.. (2018). Cytoskeleton-Associated Protein 4 Is a Novel Serodiagnostic Marker for Lung Cancer. American Journal Of Pathology. 188(6). 1328–1333. 33 indexed citations
10.
11.
Shirasawa, Masayuki, Tomoya Fukui, Yasuhiro Hiyoshi, et al.. (2018). Prognostic significance of the 8th edition of the TNM classification for patients with extensive disease small cell lung cancer. Cancer Management and Research. Volume 10. 6039–6047. 18 indexed citations
12.
Kasajima, Masashi, Satoshi Igawa, Sakiko Otani, et al.. (2017). Correlation between the efficacy of amrubicin and the previous chemotherapy regimen for relapsed small cell lung cancer. Oncology Letters. 13(3). 1719–1724. 4 indexed citations
13.
Fukui, Tomoya, Yoshiro Nakahara, Sakiko Otani, et al.. (2017). A prospective observational study of immune checkpoint inhibitor nivolumab treatment in patients with non-small cell lung cancer. Annals of Oncology. 28. x135–x135. 1 indexed citations
14.
Katono, Ken, Masayuki Shirasawa, Yoshiro Nakahara, et al.. (2016). Endobronchial involvement of mantle cell lymphoma: A case report. Respiratory Medicine Case Reports. 19. 77–79. 6 indexed citations
15.
Igawa, Satoshi, Masashi Kasajima, Michiko Kimura, et al.. (2014). Evaluation of gefitinib efficacy according to body surface area in patients with non-small cell lung cancer harboring an EGFR mutation. Cancer Chemotherapy and Pharmacology. 74(5). 939–946. 10 indexed citations
16.
Harada, Hideyuki, Takashi Seto, Satoshi Igawa, et al.. (2011). Phase I Results of Vinorelbine With Concurrent Radiotherapy in Elderly Patients With Unresectable, Locally Advanced Non-Small-Cell Lung Cancer: West Japan Thoracic Oncology Group (WJTOG3005-DI). International Journal of Radiation Oncology*Biology*Physics. 82(5). 1777–1782. 5 indexed citations
17.
Igawa, Satoshi, Haruyasu Murakami, Toshiaki Takahashi, et al.. (2009). Efficacy of chemotherapy with carboplatin and paclitaxel for unresectable thymic carcinoma. Lung Cancer. 67(2). 194–197. 64 indexed citations
18.
Fukui, Tomoya, Sakiko Otani, Ryuji Hataishi, et al.. (2009). Successful rechallenge with erlotinib in a patient with EGFR-mutant lung adenocarcinoma who developed gefitinib-related interstitial lung disease. Cancer Chemotherapy and Pharmacology. 65(4). 803–806. 28 indexed citations
19.
Igawa, Satoshi, Nobuyuki Yamamoto, Shinya Ueda, et al.. (2007). Evaluation of the Recommended Dose and Efficacy of Amrubicin as Second- and Third-Line Chemotherapy for Small Cell Lung Cancer. Journal of Thoracic Oncology. 2(8). 741–744. 32 indexed citations
20.
Igawa, Satoshi, Izumi Hayashi, Naohiko Tanaka, et al.. (2004). Nitric oxide generated by iNOS reduces deformability of Lewis lung carcinoma cells. Cancer Science. 95(4). 342–347. 11 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Shigeki Umemura Breakdown of academic impact, for papers by Yuki Matsumura Breakdown of academic impact, for papers by Adrian Langleben Breakdown of academic impact, for papers by Yuichi Sakamori Breakdown of academic impact, for papers by Y. Ichinose Breakdown of academic impact, for papers by C. A. Angeletti Breakdown of academic impact, for papers by Wieneke A. Buikhuisen Breakdown of academic impact, for papers by Kaname Nosaki Breakdown of academic impact, for papers by Eileen Regan
Rankless by CCL
2026